IGS Pharma SRL
1.0 FTEThe score of IGS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -36 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
IGS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −97,048 € | ||||
| Equity | −155,693 € | ||||
| Cash | 10,157 € | ||||
| EBITDA | 9,330 € | ||||
| Total assets | 656,335 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Jun 2026
- Year ended 31 Dec 2024filed on 03 Sep 2026
- Year ended 31 Dec 2023filed on 03 Sep 2026
- Year ended 31 Dec 2022filed on 19 Oct 2023
- Year ended 31 Dec 2021filed on 18 Oct 2022
IGS Pharma's financial analysis
- Solvency-23.7%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of IGS Pharma
IGS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0739.742.487
- VAT number
- BE0739742487
- Peppol
- Registered · 0208:0739742487 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Dec 2019
- Registered office
- 1060 Saint-Gilles
- Size
- Micro · 1.0 FTE
- Latest accounts
- 2025 · filed on 09 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
IGS Pharma (SRL) has been based in Saint-Gilles since 2019, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 97,048 € and equity of −155,693 €; its revenue is not published. With 1.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -23.7%, below the median of its sector (37.8%).
Companies similar to IGS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Cherain Retail sale of pharmaceutical products Gouvy · balance sheet 658,226 €
- T.Lamote Retail sale of pharmaceutical products Merchtem · balance sheet 663,074 €
- "Apotheek Rotti" Retail sale of pharmaceutical products Antwerp · balance sheet 656,848 €
- Bella Donna Pharma Retail sale of pharmaceutical products Scherpenheuvel-Zichem · balance sheet 655,308 €
- Geva Pharma Retail sale of pharmaceutical products Oudenaarde · balance sheet 655,182 €
- Humbeek Pharma Retail sale of pharmaceutical products Grimbergen · balance sheet 653,604 €
- Apoteek Geraerts Retail sale of pharmaceutical products Hasselt · balance sheet 660,254 €
- RAF BEX Retail sale of pharmaceutical products Leuven · balance sheet 651,970 €
Frequently asked questions about IGS Pharma
What is the revenue of IGS Pharma?
IGS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of IGS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0739742487 for IGS Pharma, if the company is VAT-registered. Its company number (CBE) is 0739.742.487.
Where is the registered office of IGS Pharma?
According to the CBE register, the registered office of IGS Pharma is in 1060 Saint-Gilles.
What is the equity of IGS Pharma?
At the close of the 2025 financial year, the equity of IGS Pharma amounts to -155,693 €, a solvency of -23.7% of total assets.
How many people work at IGS Pharma?
1.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages IGS Pharma?
The register lists 2 active mandates at IGS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of IGS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →